Clinical Oncology
Volume 22, Issue 6 , Pages 448-455, August 2010

Molecular Targeted Therapies for Patients with Refractory Thyroid Cancer

Department of Nuclear Medicine and Endocrine Oncology, Centre de Référence ‘Tumeurs Réfractaires de la Thyroïde’, Institut Gustave Roussy and University Paris-Sud XI, Villejuif, France

Received 8 February 2010; accepted 27 April 2010. published online 31 May 2010.

Abstract 

The recent availability of molecular targeted therapies leads to reconsideration of the treatment strategy in patients with distant metastases from differentiated thyroid carcinoma who are resistant to radioiodine therapy, and in patients with metastatic medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered, preferably in the context of a prospective trial.

Key words: Refractory thyroid cancer, targeted therapy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0936-6555(10)00166-4

doi:10.1016/j.clon.2010.04.008

Clinical Oncology
Volume 22, Issue 6 , Pages 448-455, August 2010

Article Tools

* Image Usage & Resolution